3-oxo-5-alpha-steroid 4-dehydrogenase 2


  • Accession: P31213
  • Swissprot: S5A2_HUMAN
  • Organism: Homo sapiens
  • Gene: SRD5A2
  • Target class: Enzyme

Drug Relations:

A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA. Bioactivity details MOA
An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA. Bioactivity details MOA
azelaic acid
Bioactivity details MOA
gamolenic acid
An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed) Bioactivity details MOA